Cargando…
A ‘Global Reference’ Comparator for Biosimilar Development
Major drug regulators have indicated in guidance their flexibility to accept some development data for biosimilars generated with reference product versions licensed outside their own jurisdictions, but most authorities require new bridging studies between these versions and the versions of them lic...
Autores principales: | Webster, Christopher J., Woollett, Gillian R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541093/ https://www.ncbi.nlm.nih.gov/pubmed/28526943 http://dx.doi.org/10.1007/s40259-017-0227-4 |
Ejemplares similares
-
An Efficient Development Paradigm for Biosimilars
por: Webster, Christopher J., et al.
Publicado: (2019) -
Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance
por: Webster, Christopher J., et al.
Publicado: (2021) -
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
por: Cohen, Hillel P., et al.
Publicado: (2023) -
Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices
por: Ebbers, Hans C., et al.
Publicado: (2016) -
Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter?
por: George, Kelly, et al.
Publicado: (2019)